24/7 Market News Snapshot 21 January, 2025 – Evolus, Inc. Common Stock (NASDAQ:EOLS)

January 21, 2025

DENVER, Colo., 21 January, 2025 (247marketnews.com) – (NASDAQ:EOLS) are discussed in this article.
Evolus, Inc. (NASDAQ:EOLS), a notable player in the performance beauty industry, has recently demonstrated impressive growth in its stock performance, with shares surging approximately 29.26% during today’s trading session, reaching $13.585 from an opening price of $12.98. This upward momentum comes as trading volume exceeds 1.10 million shares, indicative of strong investor enthusiasm. Analyst attention is keenly focused on this trend, suggesting that positive market sentiment may be fueling this notable rise.

In parallel, Evolus has issued preliminary, unaudited net revenue results for the fourth quarter and full year ending December 31, 2024, showcasing extraordinary performance. The anticipated fourth-quarter revenue of $79.0 million represents a 30% increase compared to the prior year, while full-year revenue is expected to reach $266.3 million, marking a 32% growth, thus aligning with the upper limit of the company’s guidance.

David Moatazedi, President and CEO of Evolus, attributes this achievement to effective operational strategies and significant market share gains, particularly highlighting the robust demand for the company’s flagship product, Jeuveau®, along with the international launch of Nuceiva®. The increase in customer engagement is evident, with more than 15,300 accounts placing orders for Jeuveau®, which boasts a reorder rate of approximately 70%. Additionally, Evolus Rewards, the company’s consumer loyalty program, has experienced a 40% rise in enrollment, demonstrating the brand’s commitment to enhancing customer experiences.

Looking to the future, Evolus anticipates total net revenues between $345 million and $355 million for 2025, bolstered by the upcoming launch of Evolysse™ injectable HA gels, expected to receive FDA approval in the next 90 days. The company is on track to achieve ambitious long-term financial targets, aiming for $700 million in net revenue and at least a 20% non-GAAP operating income margin by 2028. With its focus on innovation and customer engagement, Evolus is positioned to solidify its leadership in the beauty market.

Related news for (EOLS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.